Tumor-penetrating peptides: A shift from magic bullets to magic guns

Science Translational Medicine

Volumn 2, Issue 34, 2010, Pages

  Feron, Olivier ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOTENSIN II; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; BRADYKININ; CD51 ANTIGEN; ENDOTHELIN; MONOCLONAL ANTIBODY; NANOPARTICLE; NEUROPILIN 1; NITRIC OXIDE; VASCULOTROPIN; VITRONECTIN RECEPTOR; ARGINYL-GLYCYL-ASPARTIC ACID; INTEGRIN; OLIGOPEPTIDE;

ANTIANGIOGENIC ACTIVITY; BLOOD VESSEL PERMEABILITY; CANCER CELL; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RETENTION; DRUG TARGETING; GROWTH INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MOTIF; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; ARTICLE; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; PROTEIN BINDING; TRANSLATIONAL RESEARCH;

DRUG DELIVERY SYSTEMS; HUMANS; INTEGRINS; NEOPLASMS; OLIGOPEPTIDES; PROTEIN BINDING; TRANSLATIONAL RESEARCH;

EID: 77955632888     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001174     Document Type: Review

References (37)

1. S. K. Mitra, D. A. Hanson, D. D. Schlaepfer, Focal adhesion kinase: In command and control of cell motility. Nat. Rev. Mol. Cell Biol. 6, 56-68 (2005).
2. J. S. Desgrosellier, D. A. Cheresh, Integrins in cancer: Biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9-22 (2010).
3. C. J. Avraamides, B. Garmy-Susini, J. A. Varner, Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer 8, 604-617 (2008).
4. D. A. Cheresh, Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc. Natl. Acad. Sci. U.S.A. 84, 6471-6475 (1987).
5. M. D. Pierschbacher, E. Ruoslahti, Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. J. Biol. Chem. 262, 17294-17298 (1987).
6. K. N. Sugahara, T. Teesalu, P. P. Karmali, V. R. Kotamraju, L. Agemy, O. M. Girard, D. Hanahan, R. F. Mattrey, E. Ruoslahti, Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16, 510-520 (2009).
7. K. N. Sugahara, T. Teesalu, P. P. Karmali, V. R. Kotamraju, L. Agemy, D. R. Greenwald, E. Ruoslahti, Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328, 1031-1035 (2010).
8. T. Teesalu, K. N. Sugahara, V. R. Kotamraju, E. Ruoslahti, C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc. Natl. Acad. Sci. U.S.A. 106, 16157-16162 (2009).
9. S. Soker, S. Takashima, H. Q. Miao, G. Neufeld, M. Klagsbrun, Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735-745 (1998).
10. A. E. Fournier, F. Nakamura, S. Kawamoto, Y. Goshima, R. G. Kalb, S. M. Strittmatter, Semaphorin3A enhances endocytosis at sites of receptor-F-actin colocalization during growth cone collapse. J. Cell Biol. 149, 411-422 (2000).
11. M. Narazaki, G. Tosato, Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3A. Blood 107, 3892-3901 (2006).
12. A. Salikhova, L. Wang, A. A. Lanahan, M. Liu, M. Simons, W. P. Leenders, D. Mukhopadhyay, A. Horowitz, Vascular endothelial growth factor and semaphorin induce neuropilin-1 endocytosis via separate pathways. Circ. Res. 103, e71-e79 (2008).
13. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; G, Gly; K, Lys; P, Pro; R, Arg.
14. S. Lambert, M. Bouttier, R. Vassy, M. Seigneuret, C. Petrow-Sadowski, S. Janvier, N. Heveker, F. W. Ruscetti, G. Perret, K. S. Jones, C. Pique, HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165. Blood 113, 5176-5185 (2009).
15. Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392 (1986).
16. C. Bouzin, O. Feron, Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist. Updat. 10, 109-120 (2007).
17. P. Sonveaux, B. F. Jordan, B. Gallez, O. Feron, Nitric oxide delivery to cancer: Why and how? Eur. J. Cancer 45, 1352-1369 (2009).
18. P. Martinive, J. De Wever, C. Bouzin, C. Baudelet, P. Sonveaux, V. Grégoire, B. Gallez, O. Feron, Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery. Mol. Cancer Ther. 5, 1620-1627 (2006).
19. D. F. Emerich, P. Snodgrass, R. L. Dean, D. Lafreniere, M. Agostino, T. Wiens, H. Xiong, B. Hasler, J. Marsh, M. Pink, B. S. Kim, R. T. Bartus, Bradykinin modulation of tumor vasculature: I. Activation of B2 receptors increases delivery of chemotherapeutic agents into solid peripheral tumors, enhancing their efficacy. J. Pharmacol. Exp. Ther. 296, 623-631 (2001).
20. D. F. Emerich, R. L. Dean, P. Snodgrass, D. Lafreniere, M. Agostino, T. Wiens, H. Xiong, B. Hasler, J. Marsh, M. Pink, B. S. Kim, B. Perdomo, R. T. Bartus, Bradykinin modulation of tumor vasculature: II. activation of nitric oxide and phospholipase A2/prostaglandin signaling pathways synergistically modifies vascular physiology and morphology to enhance delivery of chemotherapeutic agents to tumors. J. Pharmacol. Exp. Ther. 296, 632-641 (2001).
21. C. J. Li, Y. Miyamoto, Y. Kojima, H. Maeda, Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br. J. Cancer 67, 975-980 (1993).
22. M. Suzuki, K. Hori, I. Abe, S. Saito, H. Sato, A new approach to cancer chemotherapy: Selective enhancement of tumor blood flow with angiotensin II. J. Natl. Cancer Inst. 67, 663-669 (1981).
23. P. M. Becker, J. Waltenberger, R. Yachechko, T. Mirzapoiazova, J. S. Sham, C. G. Lee, J. A. Elias, A. D. Verin, Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability. Circ. Res. 96, 1257-1265 (2005).
24. H. Jia, A. Bagherzadeh, B. Hartzoulakis, A. Jarvis, M. Löhr, S. Shaikh, R. Aqil, L. Cheng, M. Tickner, D. Esposito, R. Harris, P. C. Driscoll, D. L. Selwood, I. C. Zachary, Characterization of a bicyclic peptide neuropilin-1 (NP-1) antagonist (EG3287) reveals importance of vascular endothelial growth factor exon 8 for NP-1 binding and role of NP-1 in KDR signaling. J. Biol. Chem. 281, 13493-13502 (2006).
25. D. F. Baban, L. W. Seymour, Control of tumour vascular permeability. Adv. Drug Deliv. Rev. 34, 109-119 (1998).
26. D. R. Senger, S. J. Galli, A. M. Dvorak, C. A. Perruzzi, V. S. Harvey, H. F. Dvorak, Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985 (1983).
27. A. M. Dvorak, D. Feng, The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J. Histochem. Cytochem. 49, 419-432 (2001).
28. L. M. Acevedo, S. Barillas, S. M. Weis, J. R. Göthert, D. A. Cheresh, Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood 111, 2674-2680 (2008).
29. A. R. Reynolds, I. R. Hart, A. R. Watson, J. C. Welti, R. G. Silva, S. D. Robinson, G. Da Violante, M. Gourlaouen, M. Salih, M. C. Jones, D. T. Jones, G. Saunders, V. Kostourou, F. Perron-Sierra, J. C. Norman, G. C. Tucker, K. M. Hodivala-Dilke, Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat. Med. 15, 392-400 (2009).
30. C. L. Gladson, D. A. Cheresh, Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J. Clin. Invest. 88, 1924-1932 (1991).
31. M. Sarris, K. G. Andersen, F. Randow, L. Mayr, A. G. Betz, Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity 28, 402-413 (2008).
32. S. D. Robinson, L. E. Reynolds, V. Kostourou, A. R. Reynolds, R. G. da Silva, B. Tavora, M. Baker, J. F. Marshall, K. M. Hodivala-Dilke, Alphav beta3 integrin limits the contribution of neuropilin-1 to vascular endothelial growth factor-induced angiogenesis. J. Biol. Chem. 284, 33966-33981 (2009).
33. R. K. Jain, Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005).
34. O. Feron, Targeting the tumor vascular compartment to improve conventional cancer therapy. Trends Pharmacol. Sci. 25, 536-542 (2004).
35. M. Pàez-Ribes, E. Allen, J. Hudock, T. Takeda, H. Okuyama, F. Viñals, M. Inoue, G. Bergers, D. Hanahan, O. Casanovas, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231 (2009).
36. J. M. Ebos, C. R. Lee, W. Cruz-Munoz, G. A. Bjarnason, J. G. Christensen, R. S. Kerbel, Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239 (2009).
37. Funding: O.F. is professor at the Université catholique de Louvain and Research Director of the Fonds de la Recherche Scientifi que (FRS-FNRS). His work is supported by grants from the FRS-FNRS, the Télévie, the Belgian Fundation Against Cancer, the J. Maisin Foundation, an Action de Recherche Concertée (ARC 09/14-020) from the Communauté Française de Belgique, the Région Bruxelles-Capitale, and the Région Wallonne. Competing interests: The author has no competing interests.